NEUROMODULATION TECHNIQUES
The subject matter of the present disclosure generally relates to techniques for neuromodulation of a tissue that include applying energy (e.g., ultrasound energy) into the tissue to cause altered activity at a synapse between a neuron and a non-neuronal cell. In one embodiment, the energy is applied to cause persistent effects as a result of repeated application of energy within a predefined treatment window.
1 . A modulation system comprising:
an energy application device configured to apply energy to a region of interest in a subject, the region of interest being a sub-region of an organ comprising synapses between neuronal cells and respective non-neuronal cells; and
a controller configured to:
spatially select the region of interest;
focus the energy on the region of interest; and
adjustably control repeated application of the energy via the energy application device to the region of interest to induce repeated preferential activation of a subset of the synapses within a predefined time, the subset being located in the region of interest, to cause a persistent change to one or more molecules of interest after the repeated application of energy.
2 . The system of claim 1 , wherein the controller comprises:
a processor; and
a memory storing instructions configured to be executed by the processor to spatially select the region of interest, focus the energy on the region of interest, or control the application of the energy, or a combination thereof.
3 . The system of claim 1 , wherein the controller is configured to receive, from an assessment device, an input indicative of a concentration of the one or more molecules of interest.
4 . The system of claim 1 , wherein the organ is a liver.
5 .- 6 . (canceled)
7 . A modulation system comprising:
an energy application device configured to apply energy to a region of interest in a subject, the region of interest being a sub-region of an organ comprising synapses between neuronal cells and respective non-neuronal cells; and
a controller configured to:
spatially select the region of interest;
focus the energy on the region of interest; and
repeatedly control application of the energy via the energy application device to the region of interest to apply a low duty-cycle energy dose regimen to the region of interest, wherein the low duty-cycle dose regimen comprises a plurality of electrical stimulations that are separated by an adjustable off period of at least 4 hours, wherein the off period is determined at least in part on feedback received by the controller.
8 . A method for treating a subject having a metabolic disorder, comprising:
applying an ultrasound dose regimen to an internal organ of the subject having the metabolic disorder to treat the metabolic disorder, wherein the ultrasound dose regimen comprises a plurality of ultrasound energy doses applied at separate time points.
9 . The method of claim 8 , wherein the metabolic disorder is diabetes.
10 . The method of claim 8 , wherein the metabolic disorder is obesity.
11 . The method of claim 8 , wherein the method comprises receiving feedback from an assessment device indicative of a circulating glucose concentration after the plurality of ultrasound doses.
12 . The method of claim 11 , wherein the method comprises receiving a pre-treatment circulating glucose concentration, wherein the circulating glucose concentration after the plurality of ultrasound doses is lower than the pre-treatment circulating glucose concentration.
13 . The method of claim 12 , comprising stopping the ultrasound dose regiment after establishing a new glucose setpoint for the subject by applying the ultrasound dose regimen, wherein the new glucose setpoint is established when the circulating glucose concentration after the plurality of ultrasound doses is significantly lower than the pre-treatment circulating glucose concentration.
14 . The method of claim 13 , wherein individual doses of the plurality of ultrasound doses are separated by one or more days.
15 . The method of claim 12 , wherein the pre-treatment circulating glucose concentration, wherein the circulating glucose concentration is indicative of diabetes or prediabetes.
16 . The method of claim 13 , wherein the internal organ is a liver of the subject.
17 . The system of claim 7 , wherein the feedback is from an assessment device.
18 . The system of claim 17 , wherein the assessment device is a blood glucose monitor.
19 . The system of claim 7 , wherein the organ is a liver of the subject.
20 . The system of claim 19 , wherein the region of interest is not within distal lobes of the liver.
21 . The system of claim 19 , wherein the region of interest includes a porta hepatis of the liver.
22 . The system of claim 7 , wherein the feedback comprises a concentration of one or more hypothalamic markers.